I Grande Affiliation: Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.; M Berk Affiliation: Deakin University, IMPACT Strategic Research Centre, School of Medicine, Geelong, VIC, Australia; Florey Institute of Neuroscience and Mental Health, Orygen, The National Centre of Excellence in Youth Mental Health and Orygen Youth Health Research Centre, and Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia.; B Birmaher Affiliation: Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; E Vieta Affiliation: Bipolar Disorders Unit, Clinical Institute of Neurosciences, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. Electronic address: email@example.com.
Article : English
Lancet (London, England) 2016 Apr 09; 387(10027): 1561-72
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bipolar disorder is a recurrent chronic disorder characterised by fluctuations in mood state and energy. It affects more than 1% of the world’s population irrespective of nationality, ethnic origin, or socioeconomic status. Bipolar disorder is one of the main causes of disability among young people, leading to cognitive and functional impairment and raised mortality, particularly death by suicide. A high prevalence of psychiatric and medical comorbidities is typical in affected individuals. Accurate diagnosis of bipolar disorder is difficult in clinical practice because onset is most commonly a depressive episode and looks similar to unipolar depression. Moreover, there are currently no valid biomarkers for the disorder. Therefore, the role of clinical assessment remains key. Detection of hypomanic periods and longitudinal assessment are crucial to differentiate bipolar disorder from other conditions. Current knowledge of the evolving pharmacological and psychological strategies in bipolar disorder is of utmost importance.
Mood stabilization in the treatment of bipolar disorder: focus on quetiapine.Authors:Vieta E; Bipolar Disorders Program, Hospital Clínic, University of Barcelona, IDIBAPS, Spain. firstname.lastname@example.orgSource:Human Psychopharmacology [Hum Psychopharmacol] 2005 Jun; Vol. 20 (4), pp. 225-36.Publication Type:Journal Article; Research Support, Non-U.S. Gov’t; ReviewLanguage:EnglishJournal Info:Publisher: Wiley & Sons Country of Publication: England NLM ID: 8702539 Publication Model: Print Cited Medium: Print ISSN: 0885-6222 (Print) Linking ISSN: 08856222 NLM ISO Abbreviation: Hum Psychopharmacol Subsets: MEDLINEImprint Name(s):Original Publication: Chichester, Sussex, England : Wiley & Sons, c1986-MeSH Terms:Affect/*drug effects
Antipsychotic Agents/*therapeutic use
Bipolar Disorder/*drug therapy
Bipolar Disorder/psychology ; Depressive Disorder/drug therapy ; Humans ; Long-Term Care ; Quetiapine FumarateAbstract:The use of at least one mood-stabilizing agent is common clinical practice in the treatment of bipolar disorder, regardless of the treatment setting or disease phase. However, a consensus definition of ‘mood stabilizer’ remains to be established. A mood stabilizer has been operationally described as an agent that is useful in at least one phase of bipolar disorder while not worsening any other phase of the illness. More stringent definitions have been proposed, and it can be argued that a clinically effective mood stabilizer would have efficacy in a broad range of affective, psychotic, behavioral and cognitive domains in all phases of bipolar disorder and would be well tolerated across a range of doses for sustained periods. Clinically effective mood stabilizers should treat mania and depression, while preventing recurrence and improving quality of life. Effective treatment should not precipitate mania, depression, or rapid cycling, and should minimize the burden of treatment-emergent side effects. Data from clinical studies of quetiapine are reviewed in context with the literature discussing traditional and emerging mood stabilizers. Using a liberal definition, the evidence for quetiapine qualifies it as a bimodal mood stabilizer based on its demonstrated effectiveness in the treatment of bipolar mania and depression. Further data suggest that quetiapine has promise across all phases of bipolar disorder with the potential to meet even the most stringent definitions of a mood stabilizer.
(Copyright 2005 John Wiley & Sons, Ltd.)Number of References:82Comments:Erratum in: Hum Psychopharmacol. 2005 Jul;20(5):375.Substance Nomenclature:0 (Antipsychotic Agents)
2S3PL1B6UJ (Quetiapine Fumarate)Entry Date(s):Date Created: 20050608 Date Completed: 20051004 Latest Revision: 20151119Update Code:20161213PMID:15880391